The March for Science will be taking place this Saturday and our organization Scientists Inc is one of the supporters. Our science festival will be next week and in this medium blog post I explain why it’s on us, scientists, to bridge the gap between experts and the public and how festivals like taste of science are a valuable tool to do so.
Niccolò is a trained physician that realized that there are more ways to contribute to medicine other than seeing patients. As a result, he started a PhD at the University of Turin, Italy, working with Marco Beccuti, Francesca Cordero and Gianfranco Balbo, developing mathematical models of tumor metabolism.
After coming to Tampa last November to attend the 5th IMO Workshop, he decided that it would pay to spend more time here. So for the next half year Niccolò and us will be working together on an agent-based model of metabolic heterogeneity in cancer. Stay tuned.
One more year one more IMO Workshop. This year our group worked on CMML or Chronic MyeloMonocytic Leukemia, a relatively rare blood cancer. As usual in IMO workshops our team included clinical (physician and malignant hematology specialist Eric Padron), cancer biologists (Andriy Marusyk and Daria Miroshnychenko) and mathematical modelers from Moffitt, Cleveland Clinic, Oxford, Yale and Harvard. A crack team of interdisciplinary researchers that I was lucky to be part of.
The JAK pathway is considered a driver of CMML and fortunately a drug known as ruxolitinibruxolitinib can target cells whose growth is driven by JAK. Unfortunately, as it is the case with most targeted treatments, ruxolitinib quickly leads to the emergence of resistance and relapse. While this is not entirely surprising, the interesting bit is that neither allele frequency nor tumor burden are impacted by the treatment. What exactly drives ruxolitinib resistance?
Team member Artem Kaznatcheev has written about the basis of our project before so please start by taking a look there. Our group produced a suite of models where we consider three distinct possibilities: that there is a subtle Darwinian selection force impacting proliferation rates, that a (provocatively named) Lamarckian force is driving resistance or that non cell-autonomous mechanisms are in place. We clearly thought of something that resonated with the workshop judges as we were awarded a pilot grant to test this experimentally so stay tuned.
I am currently in a small city in Germany: Bielefeld, as a guest of the Center for Interdisciplinary Research (ZiF in German) of the University of Bielefeld. During this time I will be working with other ZiF fellows on a couple of projects which I hope to discuss some other time. This work will be within the framework of a ZiF cooperation group called Multiscale Modeling of Tumor Initiation, Growth and Progression.
To kick start this, the organizers of this cooperation group have also organized a small workshop on mathematical modelling of cancer evolution. This being exactly the topic of my research for the last decade meant I was really excited to participate. The image at the top of this post shows many (but not all) of the participants.
Any interdisciplinary meeting will include people from at least two disciplines with the goal of the meeting being to establish some sort of bridge between them. In this case I could argue that the disciplines were mathematicians working on less applied topics vs those working on more applied ones (or biologists as one of them referred to us).
But where I stand, the more interesting gap to bridge was between those interested on the genetic aspects of cancer evolution and those (me and Indiana’s James Glazier) which focused instead on the role of selection. If you ask me (and by reading these lines you have implicitly done so) both genetic variation and selection are the two pillars of evolution and should be considered equally important. Nonetheless there seems to be a lot more work done in trying to understand genetic mutations and phylogenetic trees than in trying to see how the microenvironment and interactions between different cells determines which phenotypes will succeed and which ones will not. More importantly, selection is a key aspect of evolution that we need to understand if we want to have any success when applying treatments to anything from cancer to bacteria to viruses. Why are they (apparently) vastly more people working on genetic aspects rather than selection?
I think that this difference between workflows might partly explain why. There is a wealth of biological data, much of which is genetic in nature, which requires a comparatively modest degree of collaboration with experimentalists if you are a modeler. The process is described in the previous figure: use a mathematical model to find out what the data tells you and then generate hypotheses out of it.
Working on selection requires a different approach as there’s not much data available, especially data that could be easily slotted in a mechanistic model of cancer evolution. Here the mathematical model, built after much consultation with domain experts (that is, cancer biologists) is built to explore the biology and yield hypotheses, which, since we involved our experimental partners from the start, will be also explored in vivo or in vitro. This route is harder but also relatively unexplored, want to join?
A couple of months ago we got news that the NCI has awarded us a U01 grant to continue our work defining the bone ecosystem and how prostate cancer can come in and disrupt it. Of course this is something that cannot be done in a hurry so we are in this for the long-haul. We also need help. We have Conor Lynch and his lab as the willing partners for this work but we also need you.
And who are you, you might be (weirdly) asking yourself ? A lot of what we need was described in this post. Shall I start with a PhD in physics/maths/CS? the need to be able to think mathematically and (hopefully) be able to develop in a programming language like C++/Java/Python or others of the sort? Those are a must but not the most important quality to work in a place like ours.
Basically we want you to be a detective of cancer biology, able to work with other people, happy to discuss your ideas with either mathematicians, biologists and oncologists. Gregarious but also independent you want to try new ways to think about cancer treatment
That this sound like you? Then email me and also look for job #20125 at https://moffitt.org/careers-education/
Quite the title for the post, no? We just had a paper accepted in Nature Scientific Reports entitled Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer and we thought we would share the news with you. This paper is part of our ongoing work with the Lynch lab at Moffitt to better understand the evolutionary dynamics of prostate cancer metastases in the bone. Continuing on our previous integrated computational platform [blog, description, paper] we decided to investigate a novel treatment which is not typically used in the clinic: the inhibition of the key signaling molecule TGF-Beta. If you know anything about prostate cancer research you will find TGF-Beta familiar. It has been studied to death and not much of clinical use has ever been found. The issue is that although we know a lot about it, cancer biologists have not found a model to integrate all those findings. We decided to use a computational agent-based model to integrate a lot of what we know of the biology of TGF-Beta in bone metastatic prostate cancer.
We took our previous model and worked carefully to make sure all the cell types responded to TGF-Beta to the best of the cancer biology community’s knowledge. We then went back and forth between this computational model and a mouse model in order to make sure that we could recapitulate TGF-Beta inhibition in the context of both: normal bone and cancerous bone. As you can see in the figure, one advantage of the computational model is that resolution of information about each cell type in any point of the tumor at any stage of the progression. This information can be contrasted with the relatively scarce experimental one to asses whether there are disagreements that need to be resolved.
Another advantage of the computational model is that, even if it is relatively complex like this one, it can test hypothesis at a much faster rate, for longer periods of time (and in a much cheaper and humane fashion) than mouse models. This allowed us to explore all kinds of schemes for the application of the TGF-Beta inhibitor. Once something promising is found we can then test those schemes experimentally to see how they fare with the mouse model.
What we found is that pre-application of the inhibitor is a much better option than application once the metastasis has established itself in the bone. What this could mean to a potential patient using a TGF-Beta inhibitor (which as said, is not a clinical option at the moment) is that we could give these treatments after the primary tumor has been identified in the prostate but before metastases have been found. It is important to understand though that this is the result of basic research and that this conclusion will have to remain hypothetical while we find how move our approach from a pre-clinical model to a clinical one. More importantly, what we have shown is that the integration of various sources of experimental data into a purposely made mechanistic mathematical model with the right amount of complexity (not too simple, not too complex) allows us to identify and explore novel treatments in ways (and at speeds) that would not be possible otherwise.
The second group of HIP-IMO students (High School Internship program at IMO) has arrived to Moffitt and with it, Priya Kavia. Priya is a student at Steinbrenner High in Lutz, FL and in the next few weeks she will become a mathematical oncologist working in cancer evolution and evolutionary-enlightened treatments.